In summary, our data demonstrate that PRC2 inhibition or deletion results in the upregulation and activation of BMP‐ACVR1 signaling through phosphorylation of SMAD1/5 in multiple PRC2 drug‐sensitive lymphoma cells and xenograft tumors. This evidence concerns the gene ACVR1 and lymphoma.